These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
36. The Effect of Syringe-Filling Technique on the Risk for Endophthalmitis after Intravitreal Injection of Anti-VEGF Agents. Finkelstein M; Katz G; Zur D; Rubowitz A; Moisseiev E Ophthalmologica; 2022; 245(1):34-40. PubMed ID: 34348344 [TBL] [Abstract][Full Text] [Related]
37. Current Infectious Endophthalmitis Rates After Intravitreal Injections of Anti-Vascular Endothelial Growth Factor Agents and Outcomes of Treatment. Gregori NZ; Flynn HW; Schwartz SG; Rosenfeld PJ; Vaziri K; Moshfeghi AA; Fortun JA; Kovach JL; Dubovy SR; Albini TA; Davis JL; Berrocal AM; Smiddy WE Ophthalmic Surg Lasers Imaging Retina; 2015 Jun; 46(6):643-8. PubMed ID: 26114845 [TBL] [Abstract][Full Text] [Related]
38. Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab. Fintak DR; Shah GK; Blinder KJ; Regillo CD; Pollack J; Heier JS; Hollands H; Sharma S Retina; 2008; 28(10):1395-9. PubMed ID: 18827737 [TBL] [Abstract][Full Text] [Related]
39. Prophylactic antibiotic use after intravitreal injection: effect on endophthalmitis rate. Bhatt SS; Stepien KE; Joshi K Retina; 2011 Nov; 31(10):2032-6. PubMed ID: 21659941 [TBL] [Abstract][Full Text] [Related]
40. Lid splinting eyelid retraction technique: a minimised sterile approach for intravitreal injections. Munro M; Williams GR; Ells A; Fielden M; Kherani A; Mitchell P; Ruzicki J; Adatia FA Br J Ophthalmol; 2018 Sep; 102(9):1254-1258. PubMed ID: 29246893 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]